Komori
Share Issuance and Disposal4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of Completion of Payment for the Disposal of Treasury Shares as a Restricted Stock Incentive for the Employee Stock Ownership Association and Partial Forfeiture

Payment has been completed for the planned third-party allotment of treasury shares to the employee shareholding association. As the number of employees who consented to participate in the plan has been finalized, the number of shares to be disposed of and the total disposal amount were lower than initially planned.

Worth reading
40Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
7370
Decrease in shares (from 22,198 shares to 14,828 shares)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Disposal of treasury shares as a restricted stock incentive for the Employee Stock Ownership Association (third-party allotment)

Who receives how much

14,828 common shares of the Company (before change: 22,198 shares)

あすか製薬ホールディングス従業員持株会: 14,828 shares

The lower thin line represents the existing number of shares to which these shares will be added.

¥2,259 per share
Total issue value

¥33,496,452 (before change: ¥50,145,282)

Categories and Number of Persons Covered
Employee shareholding association members (number: Not disclosed)
Payment date
2 November 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalDisposal of treasury shares as a restricted stock incentive for the Employee Stock Ownership Association (third-party allotment)
Number of shares to be issued or disposed of14,828 common shares of the Company (before change: 22,198 shares)
Issue price and disposal price¥2,259 per share
Total issue value¥33,496,452 (before change: ¥50,145,282)
Payment date2 November 2026
Intended allotteeあすか製薬ホールディングス従業員持株会: 14,828 shares
Categories and Number of Persons CoveredEmployee shareholding association members (number: Not disclosed)
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The number of members who agreed to participate in the restricted stock incentive plan for the employee stock ownership association was finalized.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the Disposal of Treasury Shares as a Restricted Stock Incentive for the Employee Stock Ownership Association and Partial Forfeiture | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori